[
  {
    "title": "海创药业(688302.SH)：PROTAC药物HP518临床试验申请获得FDA受理",
    "href": "http://stock.jrj.com.cn/2022/12/21162237228457.shtml",
    "datetime": "2022-12-21 16:22:09",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)：第三季度净亏损7465.91万元",
    "href": "http://stock.jrj.com.cn/2022/10/28014937092125.shtml",
    "datetime": "2022-10-28 01:49:45",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)：约113.59万股限售股将于10月12日上市流通",
    "href": "http://stock.jrj.com.cn/2022/09/26165437021902.shtml",
    "datetime": "2022-09-26 16:54:55",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)：上半年净亏损1.48亿元",
    "href": "http://stock.jrj.com.cn/2022/08/29223736949553.shtml",
    "datetime": "2022-08-29 22:37:45",
    "code": "688302"
  },
  {
    "title": "海创药业（688302）：于电话会议举行投资者关系活动",
    "href": "http://stock.jrj.com.cn/2022/06/02084936699153.shtml",
    "datetime": "2022-06-02 08:49:48",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)控股股东延长股份锁定期",
    "href": "http://stock.jrj.com.cn/2022/05/15155636649143.shtml",
    "datetime": "2022-05-15 15:56:55",
    "code": "688302"
  },
  {
    "title": "海创药业2022年一季度营收为0元 ：亏损8690万元 研发进度推进、投入增加",
    "href": "http://stock.jrj.com.cn/2022/05/03191136546537.shtml",
    "datetime": "2022-05-03 19:11:51",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)一季度净亏损8689.98万元",
    "href": "http://stock.jrj.com.cn/2022/04/28212336496111.shtml",
    "datetime": "2022-04-28 21:23:52",
    "code": "688302"
  },
  {
    "title": "海创药业科创板上市：跌近30% 复星与海创同力是股东",
    "href": "http://stock.jrj.com.cn/2022/04/12203736317199.shtml",
    "datetime": "2022-04-12 20:37:05",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)IPO认购结果：网上网下共弃购80.24万股",
    "href": "http://stock.jrj.com.cn/2022/04/06191536264001.shtml",
    "datetime": "2022-04-06 19:15:22",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)披露中签结果：中签号码共有1.42万个",
    "href": "http://stock.jrj.com.cn/2022/03/31191036241433.shtml",
    "datetime": "2022-03-31 19:10:07",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)：网上发行最终中签率为0.037%",
    "href": "http://stock.jrj.com.cn/2022/03/30235836212026.shtml",
    "datetime": "2022-03-30 23:58:00",
    "code": "688302"
  },
  {
    "title": "海创药业(688302.SH)IPO定价为42.92元/股 3月30日申购",
    "href": "http://stock.jrj.com.cn/2022/03/28195435925012.shtml",
    "datetime": "2022-03-28 19:54:45",
    "code": "688302"
  },
  {
    "title": "为突击IPO使出浑身解数 海创药业研发能力捉襟见肘",
    "href": "http://stock.jrj.com.cn/2021/12/09103433989211.shtml",
    "datetime": "2021-12-09 10:34:00",
    "code": "688302"
  },
  {
    "title": "为突击IPO使出浑身解数 海创药业研发能力捉襟见肘",
    "href": "http://stock.jrj.com.cn/2021/12/09103434040137.shtml",
    "datetime": "2021-12-09 10:34:00",
    "code": "688302"
  },
  {
    "title": "海创药业过会：今年IPO过关第331家 中信证券过47单",
    "href": "http://stock.jrj.com.cn/2021/09/30101333541433.shtml",
    "datetime": "2021-09-30 10:13:00",
    "code": "688302"
  },
  {
    "title": "海创药业零营收无产品3年亏6亿 拟募25亿一实控人美籍",
    "href": "http://stock.jrj.com.cn/2021/09/28071433527745.shtml",
    "datetime": "2021-09-28 07:14:00",
    "code": "688302"
  },
  {
    "title": "思科瑞、海创药业9月29日科创板首发上会",
    "href": "http://stock.jrj.com.cn/2021/09/23195833506333.shtml",
    "datetime": "2021-09-23 19:58:00",
    "code": "688302"
  },
  {
    "title": "海创药业答科创板二轮问询，股权激励、研发费用等被关注",
    "href": "http://stock.jrj.com.cn/2021/09/17170033452114.shtml",
    "datetime": "2021-09-17 17:00:53",
    "code": "688302"
  },
  {
    "title": "再下一城! 海创药业冲刺科创板IPO获上交所问询",
    "href": "http://stock.jrj.com.cn/2021/06/16092932939010.shtml",
    "datetime": "2021-06-16 09:29:17",
    "code": "688302"
  },
  {
    "title": "多家医药上市企业“加持”，尚未盈利的海创药业科创板IPO能否如愿？",
    "href": "http://stock.jrj.com.cn/2021/05/21174332794208.shtml",
    "datetime": "2021-05-21 17:43:51",
    "code": "688302"
  },
  {
    "title": "海创药业开启上市进程 9月刚完成10亿元C轮融资",
    "href": "http://stock.jrj.com.cn/ipo/2020/11/27085031357585.shtml",
    "datetime": "2020-11-27 08:50:55",
    "code": "688302"
  }
]